65,437 trials
Endometriosis
Primary: Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Week 12 — 98.6; 99.3 percentage of subjects
Non-Small Cell Lung Cancer ALK-positive · Non-Small Cell Lung Cancer c-Met Dependent · Non-Small Cell Lung Cancer ROS Marker Positive
Primary: Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib — 250; 250; 250; 250 milligram
Breast Cancer
Primary: Minimum Number of Vaccine Doses Created Using Participant Tumor Sample — 6 doses
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 4; 1; 0; 0 Participants
Lower Limb Amputation Above Knee (Injury)
Primary: Change in 6 Minute Gait Test — 380.4; 380.4; 35.9; 26.7 meters — p=0.01
Paroxysmal Atrial Fibrillation
Primary: Primary Safety: A Composite Safety Endpoint Consisting of the Subjects That Experience One or More Serious Adverse Events (SAEs) Related to the Investigational Procedure…
Healthy
Primary: Ex-vivo Inhibition Of Platelet Aggregation (IPA) — 0.82; 1.21; 1.03; 4.42 ratio
Peripheral Arterial Disease · Claudication
Primary: Patency at 12-months — 83.9; 60.6 percentage of lesions
Pain
Primary: Change in Pain Level — 1.15; -0.04; 1.07 score on a scale
Group B Streptococcal Infections
Primary: Percentage of Participants Reporting Prompted Local Reactions Within 14 Days Following Booster Dose (Redness, Swelling, and Pain at the Injection Site) — 68.4; 42.7…
Stroke
Primary: Number of Participants With Major Response — 0; 0; 0; 0 Participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC) — 162; 84; 77; 1 Participants — p=0.787
Chronic Pain
Primary: PROMIS - Pain Interference Short Form 8a — 61.68; 60.26 score on a scale — p=.541
Patients Waiting for Coronary Artery Bypass Graft Surgery · Patients Waiting for Aortic Valve Repair or Replacement · Patients Waiting for Mitral Valve Repair or Replacement
Primary: Proportion of Patients With Hospital Length of Stay Greater Than 7 Days. — 20; 16 Participants
Pain, Postoperative
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 823; 73 Participants